Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS Asset Management Americas increased its stake in Teva Pharmaceutical Industries by 5.9%, holding approximately 3.54 million shares worth about $54.37 million.
• Teva's quarterly earnings reported an EPS of $0.66, exceeding analysts' expectations, while the company had a revenue of $4.18 billion, slightly below estimates.
• Several analysts have assigned a buy rating to Teva's stock, with price targets ranging from $23.00 to $25.00, and the consensus price target averaging $24.71.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 5.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 3,537,324 shares of the company's stock after buying an additional 196,261 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.31% of Teva Pharmaceutical Industries worth $54,369,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of TEVA. Ameriprise Financial Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 3.9% in the 4th quarter. Ameriprise Financial Inc. now owns 147,649 shares of the company's stock valued at $3,254,000 after buying an additional 5,494 shares during the period. Focus Partners Wealth lifted its position in Teva Pharmaceutical Industries by 8.7% in the 4th quarter. Focus Partners Wealth now owns 38,335 shares of the company's stock valued at $845,000 after purchasing an additional 3,071 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at about $332,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Teva Pharmaceutical Industries by 122.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,048 shares of the company's stock valued at $221,000 after purchasing an additional 5,526 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its position in Teva Pharmaceutical Industries by 6.8% in the 4th quarter. Nuveen Asset Management LLC now owns 2,857,007 shares of the company's stock valued at $62,968,000 after purchasing an additional 182,774 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TEVA has been the topic of several recent research reports. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded down $0.07 during midday trading on Friday, reaching $18.38. 7,435,534 shares of the company were exchanged, compared to its average volume of 9,410,089. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a market cap of $21.08 billion, a P/E ratio of -114.88, a PEG ratio of 1.07 and a beta of 0.72. The company's 50 day moving average price is $17.51 and its two-hundred day moving average price is $16.58. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same period in the previous year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries's revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.